Shenghong Ma

is currently focusing on the mechanisms of Hippo pathway regulation.



2006-2010 B.S. Biological Science, Zhejiang University, China
2010-2015 Ph.D. Biochemistry and Molecular Biology, Fudan University, China
2016-present Postdoctoral fellow in the Department of Pharmacology, UC San Diego, CA


Selected Publications

L2hgdh deficiency accumulates L-2-hydroxyglutarate with progressive leukoencephalopathy and neurodegeneration.
Ma S, Sun R, Jiang B, Gao J, Deng W, Liu P, he R, Cui J, Ji M, Yi W, Yang P, Wu X, Xiong Y, Qiu Z, Ye D, Guan KL.
Mol Cell Biol. (2017). in press

Oncometabolite D-2-Hydroxyglutarate Inhibits ALKBH DNA Repair Enzymes and Sensitizes IDH Mutant Cells to Alkylating Agents.
Wang P, Wu J, Ma S, Zhang L, YAo J, Hoadley KA, Wilderson MD, Perou CM, Guan KL, Ye D, Xiong Y.
Cell Rep. (2015). 13:2353-2361

D-2-hydroxyglutarate is essential for maintaining oncogenic property of mutant IDH-containing cancer cells but dispensable for cell growth.
Ma S, Jiang B, Deng W, Gu ZK, Wu FZ, Li T, Xia Y, Yang H, Ye D, Xiong Y, Guan KL.
Oncotarget. (2015). 6:8606-8620

R-2-hydroxyglutarate as the key effector of IDH mutations promoting oncogenesis.
Ye D, Ma S, Xiong Y, Guan KL.
Cancer Cell. (2013). 23:274-276